Calprotectin: The Utility Of Calprotectin In Diagnosis Of Acute Appendicitis In Pediatric Patients. by Farmer, Lori
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
Summer 8-8-2014
Calprotectin: The Utility Of Calprotectin In
Diagnosis Of Acute Appendicitis In Pediatric
Patients.
Lori Farmer
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Farmer, Lori, "Calprotectin: The Utility Of Calprotectin In Diagnosis Of Acute Appendicitis In Pediatric Patients." (2014). School of
Physician Assistant Studies. Paper 480.
Calprotectin: The Utility Of Calprotectin In Diagnosis Of Acute
Appendicitis In Pediatric Patients.
Abstract
Objectives: Appendicitis can be a diagnostic dilemma in children. Current misdiagnosis rates in children can
range as high as 57%. Accurate diagnosis of appendicitis is based upon a variety of clinical scoring systems,
traditional lab biomarkers, radiological imaging studies and surgical consultations. Traditional biomarkers
provide varied degrees of accuracy and predictability based on duration of symptoms, and cut-off value used.
Investigators have researched several novel biomarkers, which may aid in increasing the diagnostic accuracy of
traditional biomarkers with the goal of reducing CT utilization and subsequent radiation exposure risks.
Calprotectin, a biomarker associated with intestinal mucosa inflammation maybe useful. What is the utility of
calprotectin in the diagnosis of acute appendicitis in children with abdominal pain?
Methods: An exhaustive search was conducted through the use of Medline/Ovid, Web of Science, CINAHL,
Evidence Based Medicine Review Multifile, and Google Scholar using the keywords: calprotectin, myeloid
related protein(MRP 8/14), S100 proteins and appendicitis. Relevant articles were assessed for quality using
GRADE. A search on the NHI clinical trials site revealed one ongoing trial related to the use of calprotectin as
part of a combination biomarker panel evaluating the panels’ diagnostic accuracy in ruling out acute
appendicitis in children with abdominal pain.
Results: Two studies met inclusion criteria and were included in this systematic review. A prospective, blind
comparison, to a gold standard study with 503 participants that demonstrated a 3-marker panel of WBC, CRP,
and calprotectin showed high sensitivity, high negative predictive value (NPV), and low negative likelihood
ratios for acute appendicitis. In comparison, a combination of WBC less than 10k/ul and normal CRP had
similar sensitivity and negative likelihood ratios, but reduced specificity and 14% more patients identified as
false positive for acute appendicitis. A second prospective, blind comparison to a gold standard, pilot study
with 176 participants demonstrated that while normal calprotectin levels showed high sensitivity and high
NPV; specificity was low at negative threshold, and a normal WBC count performed better overall.
Conclusion: Calprotectin in combination with traditional inflammatory biomarkers WBC and CRP offers
some benefit in the reduction of false positive test results in children with abdominal pain at sufficient low risk
for appendicitis; further diagnostic radiological testing may be avoided.
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Abstract 
  
Objectives: Appendicitis can be a diagnostic dilemma in children. Current misdiagnosis 
rates in children can range as high as 57%.  Accurate diagnosis of appendicitis is based 
upon a variety of clinical scoring systems, traditional lab biomarkers, radiological 
imaging studies and surgical consultations.  Traditional biomarkers provide varied 
degrees of accuracy and predictability based on duration of symptoms, and cut-off value 
used.  Investigators have researched several novel biomarkers, which may aid in 
increasing the diagnostic accuracy of traditional biomarkers with the goal of reducing CT 
utilization and subsequent radiation exposure risks.  Calprotectin, a biomarker associated 
with intestinal mucosa inflammation maybe useful. What is the utility of calprotectin in 
the diagnosis of acute appendicitis in children with abdominal pain? 
 
Methods: An exhaustive search was conducted through the use of Medline/Ovid, Web of 
Science, CINAHL, Evidence Based Medicine Review Multifile, and Google Scholar 
using the keywords: calprotectin, myeloid related protein(MRP 8/14), S100 proteins  and 
appendicitis. Relevant articles were assessed for quality using GRADE.  A search on the 
NHI clinical trials site revealed one ongoing trial related to the use of calprotectin as part 
of a combination biomarker panel evaluating the panels’ diagnostic accuracy in ruling out 
acute appendicitis in children with abdominal pain. 
 
Results: Two studies met inclusion criteria and were included in this systematic review.  
A prospective, blind comparison, to a gold standard study with 503 participants that 
demonstrated a 3-marker panel of WBC, CRP, and calprotectin showed high sensitivity, 
high negative predictive value (NPV), and low negative likelihood ratios for acute 
appendicitis.  In comparison, a combination of WBC less than 10k/ul and normal CRP 
had similar sensitivity and negative likelihood ratios, but reduced specificity and 14% 
more patients identified as false positive for acute appendicitis.  A second prospective, 
blind comparison to a gold standard, pilot study with 176 participants demonstrated that 
while normal calprotectin levels showed high sensitivity and high NPV; specificity was 
low at negative threshold, and a normal WBC count performed better overall.  
 
Conclusion: Calprotectin in combination with traditional inflammatory biomarkers WBC 
and CRP offers some benefit in the reduction of false positive test results in children with 
abdominal pain at sufficient low risk for appendicitis; further diagnostic radiological 
testing may be avoided.  
 
Key Words: Children, appendicitis, calprotectin, MRP 8/14, S100 proteins, human 
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Calprotectin: The Utility Of Calprotectin In Diagnosis Of 
Acute Appendicitis In Pediatric Patients. 
 
BACKGROUND 
 Appendicitis is the most common reason for emergency abdominal surgery  
in children.  Up to 8% of children who present urgently for evaluation of abdominal  
pain are diagnosed with acute appendicitis.  Appendicitis occurs across all age  
groups, with the highest incidence presenting in the second decade of life.  Although  
rates of appendicitis are lower in children under 5 years of age,1 they are more  
difficult to diagnose due to their limited complex verbal skills, non-specific  
presentation, and often-equivocal physical exam findings.  Despite intensive  
research and discussion, a rapid accurate diagnosis of pediatric appendicitis  
remains elusive.2 Symptom presentation is varied depending upon the age of the  
child, the duration of symptoms, and the exact position of the appendix in the  
abdomen.3    
 Children with abdominal pain, who present with non-specific clinical exams and 
equivocal physical findings, can create a diagnostic quandary that challenges standard 
diagnostic methods.  Accurate diagnosis of appendicitis is a dynamic, integrative, 
evaluation of symptoms combined with possible diagnostic studies to determine a test-
treatment threshold.  Several clinical scoring systems have been developed to assist  
with risk stratification for acute appendicitis in an attempt to define a specific  
diagnostic pathway for a child with abdominal pain.  One such tool, the Pediatric  
Appendicitis Score (PAS), published by Samuel in 2002,4 categorizes the risk of  
appendicitis in children with abdominal pain using a single discriminate value on a  
10-point scale.1  Observational studies have confirmed that children with a PAS  
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score less than or equal to 3 have a 0% to 2% risk1 of acute appendicitis.  In this  
group, further diagnostic testing may lead to increased risk of false positive results  
and greater negative appendectomy rates.5   In addition, PAS scores greater than or  
equal to 7 are associated with a 78% to 96% risk1 for acute appendicitis and  
warrant surgical consultation without further diagnostic testing.  The diagnostic  
challenge presents with PAS scores of 3 to 7, which are associated with 8% to 48%  
risk1 of acute appendicitis in children with abdominal pain.  In these children, the  
options for further evaluation include, diagnostic imaging, surgical consultation,  
observation with serial abdominal exams and laboratory testing, or a combination  
of these approaches. 
 Over the last 20 years definitive diagnosis of acute appendicitis in children  
with equivocal findings has become increasingly reliant upon diagnostic imaging.    
Abdominal CT has been shown to have sensitivity ranges from (92% to 100%) 
with associated specificity ranges from (87% to 100%).6  However, concerns  
about a significant lifetime risk for radiation induced malignancy associated with CT  
exposure, especially in the pediatric population, has prompted further research into  
alternative diagnostic strategies.4  In an effort to decrease radiation exposure  
abdominal US has been recommend by the American College of Radiology, as the  
first choice diagnostic study in children with abdominal pain described as  
suspicious for acute appendicitis.7 Studies have shown abdominal US has reported  
high specificity ranges from (88% to 98%), but sensitivity can be suboptimal (77%  to  
100%).6   US is highly operator dependent and less accurate in children with obesity  
or a rigid abdomen.  
 Traditional laboratory biomarkers WBC and CRP have been extensively  
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evaluated as to their accuracy in detecting or excluding acute appendicitis in  
children.  Results of these studies indicate that traditional biomarker values have  
sensitivity and specificity ranges that vary widely, are dependent upon symptom  
time duration and cut-off value used. 1-6, 8-11 
  Missed appendicitis is a significant concern for clinicians, who are evaluating 
children with non-specific findings. Currently misdiagnosis rates of acute appendicitis 
range from 28% to 57% in children 12 years old or younger.2  Missed appendicitis is also 
the second leading cause of malpractice judgments against emergency physicians in 
patients between the ages of 6 and 17 years.6  The goal of timely and accurate diagnosis 
for appendicitis has been, in part, a balance between perforation rates and rates of  
negative appendectomies.1  The challenge of diagnosis of acute appendicitis in  
children under the age of 5, is exemplified by perforation rates as high as 84% and  
negative appendectomy rates as high as 17%.  Appendicle perforation in children is  
rare with symptom duration of less then 12 hours but incidence steadily increases  
thereafter, and is common after 72 hours.1  Complications such has abscess, small bowel 
obstruction, prolonged hospital stays, and increased readmission rates, are frequently 
associated with perforated appendicitis.   
 Recently several novel biomarkers have been investigated as to their  
potential role in achieving a goal of rapid, accurate diagnosis of acute appendicitis in  
children, while minimizing the risks associated with ionizing radiation exposure. 4,6,9     
A previous study,11 which included both adults and children, indicated a significant  
correlation between calprotectin and CRP, and calprotectin and WBC.  Calprotectin  
is a calcium binding protein released from the cytoplasm of neutrophils in  
association with inflammation.  It has been shown to participate in the recruitment  
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of leukocytes to inflamed intestinal tissue, which may make it a useful marker for  
acute appendicitis.12  Typically, in order to measure calprotectin levels, most laboratories 
utilize some version of an enzyme-linked immunoassays (ELISA).  In a study by Mills et 
al13 investigators performed a stability study on a calprotectin ELISA.  They found that 
precisions in immunoassay results are often highly time and processing dependent.  
Specifically, a processing time delay produced inflated values that increased sensitivity 
and decreased specificity.13 Recently, an investigational, rapid lateral flow assay was 
developed, by Venaxis Inc.,14 which mathematically combines calprotectin with WBC 
and CRP to produce a single numerical value.4  This value may offer an  
improvement over individual markers in the diagnosis of acute appendicitis.  This leads 
to the question; what is the utility of calprotectin in diagnosis of acute appendicitis in 
pediatric patients with abdominal pain consistent with lower risk for appendicitis?  
METHODS 
 An exhaustive literature search for available studies, which addressed the 
utilization of calprotectin in children with abdominal pain when acute appendicitis is part 
of the differential, was conducted through the use of Medline/Ovid, Web of Science, 
CINAHL, Evidence Based Medicine Review Multifile, and Google Scholar.  The search 
terms calprotectin, myeloid related protein (MRP 8/14), S100 proteins, and appendicitis 
were used.  Studies conducted on children and in the English language were additional 
limitations.  A further bibliography search for calprotectin or MRP 8/14 in association 
with appendicitis in children was performed on studies, which met inclusion criteria.  
After scanning abstracts for defined inclusion criteria, selected full-length texts were 
assessed for eligibility.  Of those texts, studies were then excluded on the basis of 
duplication, if they were review articles and if they included a study population older 
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than 20 years. Further evaluation for validity and bias was conducted utilizing a critical 
appraisal method.   Grading Recommendations, Assessment, Development, and 
Evaluation (GRADE)15 subjected the final articles that met all the inclusion criteria to 
quality assessment criteria as defined.  A search on NIH16 clinical trails site revealed one 
ongoing study, addressing the potential diagnostic utilization of a combination biomarker 
panel, which incorporates calprotectin, in children, with abdominal pain suggestive of  
acute appendicitis.  The primary study completion date was given as February 2014.  
RESULTS 
 The initial search revealed thirty-two abstracts that were evaluated and  
screened for inclusion criteria.  After screening, eight full-length text articles were 
reviewed for eligibility; of which, six were excluded for failure to meet eligibility criteria.  
At completion of the screening process, two prospective blind comparison to a gold 
standard, studies remained. Both studies were subjected to further systematic review.6,10 
(See Table 1.) 
A Novel Biomarker Panel to Rule Out Appendicitis in Pediatric Patients With 
Abdominal Pain.  
 This prospective blind comparison to a gold standard study6 investigated a  
new biomarker panel with potential sufficient sensitivity and negative predictive  
value to allow for successful identification of children with abdominal pain, at low  
risk for appendicitis, in order to avoid unnecessary imaging.  The study enrolled  
569 pediatric patients with abdominal pain, who presented at 12 different,  
emergency departments located in children’s hospitals, tertiary care centers, and  
community hospitals.  Sixty-Six patients were excluded for ineligibility, lack of  
adequate test samples, or invalid test results.  Of the remaining 503 participants,   
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351 came from large academic children’s hospitals or tertiary care centers.  
Eligibility criteria included children, age 2 to 20 years, with right lower quadrant or 
generalized abdominal pain associated with additional signs and symptoms suspicious for 
or consistent with acute appendicitis and symptom duration of less then 72 hours.6   
 The primary study intentions were to analyze the diagnostic accuracy of  
individual plasma biomarkers and combinations of such markers to rule out acute  
appendicitis in pediatric patients with abdominal pain and whose differential  
diagnosis included appendicitis.  The gold standard reference measurement of  
primary outcomes was the presence or absence of acute appendicitis, defined by a  
surgical pathology report for those who had an appendectomy and a discharge  
diagnosis for those without an appendectomy.  Follow-up on patients discharged with a 
diagnosis other than appendicitis, consisted of a review of the hospital records of all 
enrolled patients for return visits within 72 hours of discharge; any discharged patient 
who returned to the same institution with ongoing symptoms would be captured.  The 
secondary outcomes and end points were the utilization rate of CT scanning and potential 
reduction of unnecessary CT scans for those with negative biomarker results should the 
biomarkers provide adequate diagnosis for absence of acute appendicitis.6   
  After an in-depth post hoc analysis of several individual plasma biomarkers  
and combinations of such markers, investigators discovered that the combination of  
WBC, CRP, and MRP 8/14 (also known as calprotectin) provided an optimum panel.   
This biomarker panel used three individual markers combined with a mathematical  
algorithm which were converted into single value with an appropriate cut-off that 
provided a diagnostic tool with a high negative predictive value (NPV).  The cut-off was 
selected for clinical utility maximizing the number of true negative test results, while 
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minimizing the number of false negative results.  Serum samples were obtained on all 
participants based solely on presenting symptoms, thereby avoiding any bias that might 
be introduced by a preceding diagnostic evaluation. The samples were initially 
centrifuged, frozen, and sent to a research laboratory where they were later thawed and 
tested using a new MRP 8/14 lateral flow assay developed by Venaxis, Inc.6    
 The biomarker panel identified 160 patients out of 503 as negative, of those  
155 were true negatives and 5 were false negatives.  Biomarker panel sensitivities,  
specificities, NPV and likelihood ratios are listed in Table 2.  Study investigators also 
compared the algorithm to a combination of normal WBC (<10 k/ul) and, normal  
CRP (<0.8 mg/dl).  Used as a negative predictor when both WBC and CRP were  
normal, sensitivities and NPV were comparable to the biomarker algorithm, but  
specificity was diminished and there were 34 fewer patients identified as true  
negatives with one fewer false negative.6 (See Table 2.) 
 Further examination of the outcomes, revealed a significant increase in  
sensitivity and NPV with duration of symptoms lasting between 24 to 48 hours.   
However, specificity values remained unchanged (see Table 3).  Of note, is the fact that 
all five of the patients with false negative biomarker panel results had a symptom  
duration of less than 24 hours, including two with symptoms for less than 12 hours.6 
 The secondary outcome measure of the potential impact of the biomarker  
panel on reduction of CT utilization, indicated that 185 out of 503 patients in the  
cohort received a CT scan.  Of those, 60 patients had a negative biomarker panel,  
which represented 32.4% of all CT scans preformed. If those patients had been  
followed clinically rather than referred for immediate CT imaging, there could have  
been a potential reduction of 1/3 in CT utilization at initial presentation. The  
 13 
authors did, however, note that this estimate may be generous, as some patients with  
negative biomarker results may still be referred for CT imaging if there is high clinical  
suspicion, or other pathology in addition to acute appendicitis being considered.4 
 The authors primary concern was the lack of formal follow-up for  
those patients discharged from the Emergency Department (ED)with a diagnosis other 
then acute appendicitis.  They acknowledged that due to the small number of patients 
with acute appendicitis and false-negative biomarker results, a single missed false- 
negative patient could have a significant effect on the results of the study. 6 
Novel Serum And Urine Markers For Pediatric Appendicitis 
 This prospective, blind comparison to a gold standard pilot study,9 examined  
two novel biomarkers, calprotectin and leucine-rich glycoprotein-1 (LRG), for the  
purpose of determining the diagnostic relationship between serum and urine levels  
of these biomarkers and appendicitis in children with abdominal pain.  Study  
researchers also investigated the optimal thresholds of each marker that could  
potentially be used to diagnose or exclude acute appendicitis.9 
 The study enrolled 176 patients with abdominal pain who presented to an  
urban, tertiary care, pediatric emergency department from July 2009 to April 2010.  
All study participants had a standard WBC drawn in addition to investigational  
biomarker samples.  Plasma samples for calprotectin analysis were successfully  
obtained on 153 patients.  Urine samples for calprotectin were obtained on 137  
patients.  Eligibility criteria included children with abdominal pain less then 96  
hours’ duration, aged 3 to 18 years and with possible appendicitis.  
Investigators defined “possible appendicitis” as the treating physician choosing to  
obtain blood tests, radiologic studies, CT and/or US, or surgical consultation for the  
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purpose of diagnosing appendicitis.9 
 The primary study intentions were to evaluate the association of calprotectin and  
LRG with acute appendicitis, and to identify potential thresholds, which could be  
used to diagnose or exclude appendicitis.  The primary gold standard outcome  
measurement was the presence or absence of appendicitis defined by a  
histopathology report of a positive surgical appendectomy.  For patients who did  
not have surgery, this outcome was determined by a follow-up telephone call 14 days to  
21 days after the index ED visit.  Investigators completed follow-up on 99%  
patients who did not undergo surgery.9 
 The 153 plasma samples obtained on enrolled study participants were  
initially centrifuged, during weekdays from 09:00 to 16:00 and were immediately  
frozen.  During evenings and weekends, samples were initially centrifuged, then stored at 
4 degrees Celsius, until the next business day when they were frozen.  Frozen samples 
were later sent to a research laboratory where they were thawed and analyzed utilizing  
ELISA according to the manufacturer’s recommended procedures.9 
 ELISA results indicated median serum levels of calprotectin exhibited  
statistically significant elevations in association with acute appendicitis.  When  
stratified according to severity of disease, plasma levels of calprotectin were  
highest in children with perforated appendicitis compared to non-perforated  
appendicitis.  Following a similar pattern, levels remained higher in non-perforated  
appendicitis compared to non-appendicitis. However, urine calprotectin levels  
showed no statistical difference among the groups.9   
 Determining area under the curve (AUC), assessed accuracy for each biomarker.  
The AUC for serum calprotectin was (0.68, 95% CI 0.59 to 0.79).  In comparison the 
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AUC for the WBC count was notably higher (0.82 95% CI 0.75 to 0.90).  Threshold 
levels for calprotectin were determined which provided 100% sensitivity, although the 
specificity remained low (see Table 2).  Study investigators also completed an 
exploratory analysis of a combination of WBC and plasma calprotectin which led to 
improved specificity; however, sensitivity remained unchanged at 100%.9 
 Lab personnel, who were blinded to the diagnosis of enrolled patients, detected  
calprotectin levels via a commercially available ELISA kit.  The assay required a 4-hour 
processing time to be completed in a research laboratory with particular expertise in 
biomarker discovery.  Investigators also expressed concern that the small size of the 
study population limited the strength of their preliminary, exploratory results that 
suggested a potential benefit of combining calprotectin with a standard WBC.  To be 
clinically useful, results would need to be validated by larger studies.    
DISCUSSION 
 Children, who present with unequivocal clinical exams for the presence or 
absence of acute appendicitis often, provide a clear diagnostic path for the clinician to 
follow.  Adversely, children, who present with equivocal findings, can be challenging to 
diagnose and can have potentially high-risk outcomes associated with misdiagnosis.  
Utilization of diagnostic CT imaging has provided accurate, highly sensitive and specific 
diagnostic results but is associated with significant increased malignancy risks.6,4,17  
Ultrasound has optimal accuracy if visualization of appendicitis is achieved , but is less 
efficient at reassuring absence with lack of visualization. Traditional inflammatory 
biomarkers WBC and CRP are a much lower risk diagnostic approach. However, in 
children, they have provided varied degrees of sensitivity and specificity depending on 
cut-off values used and duration of symptoms present. Investigators have been exploring 
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other possible biomarkers such as calprotectin, which may improve the accuracy of 
traditional biomarkers ability to differentiate which children need to undergo additional 
potentially higher risk diagnostic evaluations.     
   The results from the two studies reviewed,6,9 indicated that calprotectin exhibited 
high sensitivity, high negative predictive value and low negative likelihood ratios both 
individually and in combination with traditional biomarkers WBC and CRP. (See Table 
2.)  A combination of normal WBC (<10 k/ul) and CRP results, also exhibited 
statistically similar sensitivity, negative predicative value, and low negative likelihood 
ratios.  Although, the biomarker algorithm did increase specificity over the combination 
of normal WBC (<10 k/ul) and CRP and allowed for a 14% reduction in false positive  
patients with an increase of one more false negative patient.  Significantly, investigators 
noted that all false negative patients had symptoms present for less than 24 hours.6 In 
addition, the study by Kharbanda et al9 noted that a normal WBC (<8.85 k/ul), provided 
both a 100% sensitivity and a higher specificity when compared to a normal calprotectin 
value.  Kharbanda et al9 also performed an exploratory analysis of combined normal 
calprotectin and WBC.  Results of combination again showed good sensitivity with an 
increased specificity of 52% (no confidence intervals provided).  Both of these studies,6,9 
demonstrated an increase in specificity with the addition of calprotectin in the diagnostic 
approach.  This translated into a lower rate of false positive results potentially leading to 
fewer children undergoing unnecessary diagnostic imagery.  
 Duration of symptom time appears to be a significant factor, in regards to the 
estimated sensitivity and negative predictive values of inflammatory biomarkers.  
Distinctly, in respect to the combination biomarker panel (calprotectin, WBW, and CRP) 
optimal sensitivity was achieved in patients with symptom duration from 24 hour to 48 
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hours in length.6   Nonetheless, specificity values remained unchanged and confidence 
intervals narrowed with symptom duration greater than 24 hours.  See Table 3.  Huckins 
et al,6 did not perform an additional sub-group analysis of the biomarker algorithm panel 
to the combination of normal WBC (<10 k/ul) and CRP based on time of symptom 
duration.  Kharbanda et al,9 did not address variability in accuracy of sensitivity of 
calprotectin and WBC count related to symptom duration.  While not addressed in these 
studies, further investigation into the effect of symptom duration on sensitivity, negative 
likelihood ratios, and NPV of optimally determined normal, combined WBC and CRP 
values, as compared to the three marker panel, may provide an additional insight into the 
potential benefit of a calprotectin incorporated panel over traditional biomarker 
combinations.  
 The type of biomarker assay method used may be another critical factor to 
consider in determining the diagnostic accuracy and efficiency of calprotectin.  The 
Huckins et al6 study, utilized a new investigational lateral flow assay panel, which 
mathematically combined the three identified biomarker values (WBC, CRP and 
calprotectin) into a single numerical value.  The panel was designed to provide rapid, 
reproducible results in urgent or emergent health care settings with the goal of effectively 
ruling out the presence of acute appendicitis in children with abdominal pain, who are at 
lower risk for acute appendicitis; reducing the need for further radiological diagnostic 
studies.  The Kharbanda et al9 study, utilized a commercially available ELISA assay 
which measured individual calprotectin levels and provided quantified results.  The assay 
took 4.5 hours to complete, in a research laboratory, which can be an obstacle for the 
clinical goal of rapid exclusion of appendicitis in children with abdominal pain and 
equivocal clinical findings.  Both studies6,9 utilized serum samples for the assay that were 
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obtained at the time of enrollment in the ED, centrifuged locally, frozen and assayed later 
in research laboratories.  An important concern is that the samples tested were not  
fresh on-site samples as would be typically be done in clinical practice.  For instance, in a 
a recent study by Mills et al13 which utilized an investigational calprotectin ELISA, 
investigators found that despite careful adherence to manufactures recommended 
processing methods, measured values can increase by 13% to 43% due to shipping effect 
and delay in analysis.13 If these values were not addressed and adjusted for, falsely 
elevated sensitivity and falsely decreased specificity values occurred. 
  Both studies indicated that calprotectin levels are elevated in children  
with acute appendicitis and may have a role improving the reliability and accuracy  
of traditional inflammatory biomarkers as negative predictors in children.6,9   However, 
both studies also had several limitations:  First, both studies utilized cohorts from  
convenience sampling methods which can be problematic; there may be a difference  
between people who choose to participate and those who do not.  Second, both of the  
study settings were disproportionately located in urban, specialty hospitals where the 
incidence of children with appendicitis and availability of diagnostic resources may be 
different from community hospitals.6,9  Third as previously addressed above, both studies 
used frozen samples assayed at a later date, which may affect accuracy of results.   
  Moreover, the Huckins et al6 study, was an industry funded, futility analysis 
looking at the accuracy of an investigational rapid biomarker panel which has been 
patented and is currently being marketed to investors explicitly for the purpose of rapid  
accurate exclusion of acute appendicitis in children who present with abdominal  
pain and have lower risk profiles for appendicitis.  Another significant limitation to  
this study6 is the lack of formal follow-up on patients discharged.  Because of the  
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small number of patients with acute appendicitis, a single missed false negative  
patient would have significant effects on study outcomes.6.  The Kharbanda et al9 study, 
was a single-center, pilot study with a small sample size.  Small population samples can 
have the potential to lead to lack of precision in results.  The study also primarily 
evaluated the diagnostic accuracy and utility of calprotectin and WBC as individual 
biomarkers and only addressed the potential benefit of combined WBC and calprotectin 
as part of a preliminary exploratory analysis with limited data published.   Therefore, 
after a detailed assessment of both studies strengths and limitations, an overall combined 
quality of evidence of the articles reviewed is low to very low, as based upon the 
GRADE criteria.15 A weak recommendation for the utility of calprotectin in diagnosing 
acute appendicitis can be given based upon the low quality evidence supporting the 
benefit of combined calprotectin, WBC and CRP over the use of standard WBC and 
CRP.   
CONCLUSION 
 In children, who have abdominal pain and an equivocal clinical exam for acute 
appendicitis, biomarker panel results (calprotectin, WBC and CRP) offered some benefit 
over WBC and CRP values in reducing false positive results for acute appendicitis; 
potentially decreasing the need for further radiological testing.  Notably, in the same 
population of children, biomarker panel results (calprotectin, WBC and CRP) 
demonstrated only moderate accuracy in identifying true negative results; thereby, 
leaving a significant population of children, who may likely require further radiological 
testing.  Further research, which is currently ongoing is likely to have an important 
influence on the confidence of the recommendation and may change the 
recommendation.   
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TABLE 1 GRADE Quality Assessment And Recommendation   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                 
a Convenience non consecutive sampling 
b Industry funded study with 5 of the 6 study investigators indicate positive conflict of 
interest statements   
c Convenience non consecutive sampling 
d Small sample size, Single center pilot study  
Quality Assessment  
Importance  Downgrade Criteria 
Quality 
 Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Huckins et al.6  A novel biomarker panel to rule out acute appendicitis in 
pediatric patients with abdominal pain    
 
Prospective Blind 
comparison to a gold 
standard 
Very 
serious 
limitations a 
No serious 
indirectness 
 No Serious 
imprecision  
No serious 
inconsistency  
Publication 
bias likelyb   Very Low Critical 
Kharbanda et al.9  Novel Serum and Urine Markers for Pediatric Appendicitis    
 
Prospective Blind 
comparison to a gold 
standard 
Serious 
limitationsc 
No serious 
indirectness 
Serious 
limitationd 
No serious 
inconsistencies 
No bias 
likely low Critical 
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TABLE 2 Summaries Of Overall Findings 
 
   Study  Biomarker Diagnostic test   Outcomes  
Sensitivity Specificity  Negative Predictive Value  LR- LR+ 
Huckins et al 6 
 
503 enrolled and sampled  
Biomarker panel: WBC, CRP, MRP 
8/14/calprotectin  
96.5% (95% CI, 92%-99%) 43.2% (95% CI, 38%-48%) 96.9% (95% CI, 93%-99%) LR- 0.081 LR+ 1.70 
 WBC ( <10 k/ul) + CRP(<0.8 
mg/dl) 
 
97.2% (95% CI, 93%-99%) 33.7% (95% CI, 29%-39%) 96.8% (95% CI, 92%-99%) LR- 0.083 LR + 1.47 
 
Kharbanda et al9 
 
176 enrolled: 153 plasma tested 
                        
Plasma calprotectin (<159 ng/ml) 
 
100% ( 95% CI, 91%-100%) 27% (95% CI, 19%-37%) 100% (95% CI, 81%-100%)  LR- 0.0 LR+ 1.37 
WBC (<8.85% k/ul) 
 
100% (95% CI, 91%-100%) 42% (95%, CI 38%-56%) 100% (95%CI 91%-100%) LR- 0.0  
LR+ 1.72 
Exploratory analysis: 
 WBC + calprotectin  
100%  52%  LR- 0.0 LR + 2.08 
 
 
TABLE 3 Summaries Of Duration Of Symptoms Biomarker Panel Findings 
 
Huckins  et al 6 
 
503 enrolled and sampled  
Duration of symptoms  
 
Outcomes  
Sensitivity  Specificity  Negative Predictive Value  LR- LR+ 
<24 hours 94.4% (95% CI 88%-98%) 43.3% (95% CI 37%-50%) 95.1% (95% CI 89%-98%) LR- 0.129 LR+ 1.66 
>24hours 100% (95% CI 94%-100%) 43.0% (95% CI 94%-100%) 100% (95% CI 94%-100%) LR- 0.0 LR+ 1.76 
 
 
Sensitivity: True Positive Results / (True Positive Results + False Negative Results) = True Positive Rate, the percentage of positive test 
results in patients who have the disease.  Negative results with high sensitivities rules diagnosis out 
 
Specificity: True Negative Results/ (True Negative Results +False Positive Results) = True Negative Rate, the percentage of negative test 
results in patients who do not have the disease.  Positive results with high specificities rules diagnosis in 
 
 
 
 
 
